- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| So | Amgen declares $2.38 dividend | 21 | Seeking Alpha | ||
| Fr | Amgen Announces 2025 Fourth Quarter Dividend | 833 | PR Newswire | THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the... ► Artikel lesen | |
| Fr | Amgen declares $2.38 per share dividend for fourth quarter 2025 | 16 | Investing.com | ||
| Fr | Amgen's Repatha reduces CV events in patients without prior heart attack | 20 | Investing.com | ||
| Fr | Amgen Stock: Analyst Estimates & Ratings | 18 | Barchart.com | ||
| Mi | Amgen's Q3 Earnings in the Cards: Here's What to Expect | 30 | Zacks | ||
| AMGEN INC CDR Aktie jetzt für 0€ handeln | |||||
| 22.10. | AstraZeneca and Amgen's Tezspire approved in EU for nasal polyps | 17 | Investing.com | ||
| 22.10. | AstraZeneca And Amgen's Tezspire Approved In EU For Severe Nasal Polyps | 396 | AFX News | THOUSAND OAKS (dpa-AFX) - AstraZeneca (AZN) and Amgen (AMGN) announced that Tezspire (tezepelumab) has received European Union approval as an add-on therapy with intranasal corticosteroids for... ► Artikel lesen | |
| 20.10. | Amgen, AZ's Tezspire challenges Dupixent in nasal polyps | 9 | pharmaphorum | ||
| 18.10. | Amgen And AstraZeneca's TEZSPIRE Approved For Epithelial-Driven Nasal Inflammation | 621 | AFX News | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) and AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved TEZSPIRE (tezepelumab-ekko) as an add-on maintenance treatment... ► Artikel lesen | |
| 17.10. | Amgen and AstraZeneca says US FDA broadens indication for Tezspire | 10 | Alliance News | ||
| 17.10. | Amgen, AstraZeneca gets FDA nod for Tezspire | 15 | Seeking Alpha | ||
| 17.10. | Amgen: FDA Approves Tezspire For Chronic Rhinosinusitis With Nasal Polyps | 1.833 | PR Newswire | Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven Inflammation
THOUSAND OAKS, Calif., Oct. 17, 2025 /PRNewswire/... ► Artikel lesen | |
| 17.10. | Price Over Earnings Overview: Amgen | 16 | Benzinga.com | ||
| 10.10. | Here's What to Expect From Amgen's Next Earnings Report | 23 | Barchart.com | ||
| 07.10. | Amgen Unveils New DTC Program, Cuts Cholesterol Drug Price by 60% | 5 | Zacks | ||
| 06.10. | Amgen To Offer Cholesterol Drug At 60% Discount As Trump Administration's Call To Lower Drug Prices | 7 | Benzinga.com | ||
| 06.10. | Amgen unveils DTC platform with 60% discount on Repatha, giving US lowest price of G7 nations | 5 | FiercePharma | ||
| 06.10. | Amgen to offer Repatha at 60% discount to U.S. consumers | 6 | Seeking Alpha | ||
| 06.10. | Amgen Launches AmgenNow, Direct-to-patient Program; Available To Repatha Patients | 480 | AFX News | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha or evolucumab. Repatha will be available through AmgenNow at a... ► Artikel lesen |
1 2 3 4 5 Weiter >>
294 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 69,80 | +0,17 % | Novartis will US-Biotech Avidity Biosciences für 12 Mrd USD übernehmen | DJ Novartis will US-Biotech Avidity Biosciences für 12 Mrd USD übernehmen
Von Dylan Tokar und Peter Loftus
DOW JONES--Novartis will den US-Biotech-Konzern Avidity Biosciences für 12 Milliarden... ► Artikel lesen | |
| QIAGEN | 40,760 | +0,90 % | Dax lässt nach - Merck und Qiagen gefragt | Frankfurt/Main - Zum Wochenausklang hat der Dax nachgelassen. Zum Xetra-Handelsschluss wurde der Index mit 23.958 Punkten berechnet, ein Minus in Höhe von 0,7 Prozent im Vergleich zum Vortagesschluss.... ► Artikel lesen | |
| CABALETTA BIO | 3,625 | +47,66 % | Cabaletta Bio Reports Positive Rese-cel Data Across Myositis, SSc, and SLE Trials | ||
| RECURSION PHARMACEUTICALS | 5,500 | -2,31 % | Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? | ||
| EVOTEC | 7,054 | -0,59 % | EQS-News: Evotec SE: Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt
27.10.2025 / 07:30 CET/CEST
Für... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 8,560 | +1,66 % | Morning Market Movers: Ventyx Biosciences, Brera Holdings, Safe & Green Holdings, American Rebel Holdings See Big Swings |
CANBERA (dpa-AFX) - At 8:05 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| RANI THERAPEUTICS | 2,185 | +52,80 % | Rani Therapeutics schließt Privatplatzierung ab und besetzt Vorstand neu | ||
| BIONTECH | 90,40 | +0,22 % | Turbulenzen im Biotechsektor - BioNTech, CureVac, Moderna, Vidac Pharma | Nach der stetigen Eskalation im Handelskrieg der beiden führenden Wirtschaftsnationen der Welt, USA und China, meldete der US-Finanzminister Scott Bessent, dass er zuversichtlich bezüglich des Treffens... ► Artikel lesen | |
| DYNE THERAPEUTICS | 22,580 | -4,08 % | Why Dyne Therapeutics Stock Crushed the Market on Monday | ||
| BEAM THERAPEUTICS | 24,995 | +5,09 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| IMMUNOVANT | 24,700 | -0,44 % | Immunovant gains amid takeover speculation | ||
| ARCUTIS BIOTHERAPEUTICS | 25,320 | +1,61 % | Arcutis Biotherapeutics, Inc.: Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results | Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025 ZORYVE cream 0.05% received U.S. Food and... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 81,40 | +3,75 % | Morning Market Movers: Picard Medical, Qualigen Therapeutics, Inhibrx Biosciences, MidWestOne Financial GroupSee Big Swings | BEIJING (dpa-AFX) - At 7:45 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,900 | +1,45 % | Summit Therapeutics: Daten überzeugen - BioNTech beobachten! | Am morgigen Dienstag neigt sich die Jahrestagung der European Society for Medical Oncology (ESMO) in Berlin schon wieder dem Ende entgegen. Zahlreiche Unternehmen haben bereits am Wochenende frische... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 33,320 | +3,25 % | Structure Therapeutics stock rating reiterated at Piper Sandler ahead of key data |
AMGEN INC CDR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,75 % bei einem Aktienkurs von 13,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AMGEN INC CDR finden Sie auf Wallstreet Online.